CLPBF (Coloplast AS) Tax Provision: $-210 Mil (TTM As of Mar. 2026)


CLPBF Coloplast AS CLPBF
72 GF Score
Price $61.76
GF Value $126.21
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Tax Provision?

Coloplast AS CLPBF +2.43% 72 Tax Provision is $-210 Mil as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.21 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Coloplast AS's tax provision for the three months ended in Mar. 2026 was $42 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $-210 Mil.

Coloplast AS Tax Provision Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Tax Provision Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -222.76 -189.04 -177.74 -199.91 -396.45

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.92 -83.02 -106.94 -61.77 42.23
CLPBF
72GF Score
Coloplast AS CLPBF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-210 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-210 Mil mean?
Coloplast AS (CLPBF) has a Tax Provision of $-210 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Tax Provision too high?
Coloplast AS's current Tax Provision is $-210 Mil. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Tax Provision compare to ISRG and BDX?
Coloplast AS's Tax Provision of $-210 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Medical Devices & Instruments company?
A good Tax Provision depends on the Medical Devices & Instruments industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Coloplast AS and its competitors. Coloplast AS's current Tax Provision is $-210 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.21, compared to a current price of $61.76 — trading 51.1% below its estimated fair value. The current Tax Provision is $-210 Mil. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Tax Provision is $-210 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBF) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $61.76 is trading 51.1% below its estimated GF Value™ of $126.21. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBF:

  • Tax Provision: $-210 Mil
  • GF Value™: $126.21 vs. price of $61.76 (51.1% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score

Get the complete analysis for CLPBF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.76
Price
$126.21
GF Value